Publication | Open Access

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial

ThrombosisHematologyPatient SafetyRivaroxaban VersusPost-discharge ThromboprophylaxisPharmacotherapyCoagulopathyMedicineAnticoagulantEmergency MedicineCovid-19